Bristol Myers Squibb reports ACTION-1 results. Bristol Myers Squibb stock trades at EUR 53.39

Bristol Myers Squibb reported positive interim results from the ACTION-1 Phase 3 trial on October 12, 2026, according to the Bristol Myers Squibb release. In weekend trading at Lang & Schwarz on October 18, 2026, Bristol Myers Squibb stock was at EUR 53.39 at 5:10 p.m. CEST.

Weekend trading

Lang & Schwarz showed a EUR 53.39 price for Bristol Myers Squibb stock at 5:10 p.m. CEST on October 18, 2026. Xetra and the primary exchanges were closed for the weekend. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.

The week in figures

The available weekend indication from Lang & Schwarz was EUR 53.39 at 5:10 p.m. CEST on October 18, 2026.

Chronology of the week

On October 12, 2026, Bristol Myers Squibb announced positive topline results from the planned interim analysis of ACTION-1. The company said the study met its primary endpoint, with a statistically significant and clinically meaningful improvement in progression-free survival. The trial evaluates RYZ101 against investigator’s choice of standard of care in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. These statements are from the company announcement.

Dates of the coming week

Bristol Myers Squibb said it will announce third-quarter 2026 results on October 29, 2026, with an investor conference call beginning at 8:00 a.m. ET. The date and call time were provided in the company’s investor-relations release. The next Xetra session is scheduled for October 19, 2026.

Market context: Market report S&P 500.